proprotein convertase subtilisin/kexin type 9 (PCSK9)

View All

pcsk9-inhibitors-for-cholesterol-management
PCSK9 Inhibitors: A New Era for Cholesterol Management

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...

Find More

Delveinsight
New Approach Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

Introduction: Cardiovascular disease is the leading cause of mortality worldwide due to increased level of Low Density Lipoprotein, cholesterol, which is a major modifiable risk factor. One of the risk factors is atherosclerosis caused when high levels of LDL-C in the blood build up in the inner walls of arteries, t...

Find More